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Abstract: Human NAD(P)H:quinone oxidoreductase 1 (NQO1) is a multi-functional protein whose 
alteration is associated with cancer, Parkinson’s and Alzheimer´s diseases. NQO1 displays a 
remarkable functional chemistry, capable of binding different functional ligands that modulate its 
activity, stability and interaction with proteins and nucleic acids. Our understanding of this 
functional chemistry is limited by the difficulty of obtaining structural and dynamic information on 
many of these states. Herein, we have used hydrogen/deuterium exchange monitored by mass 
spectrometry (HDXMS) to investigate the structural dynamics of NQO1 in three ligation states: 
without ligands (NQO1apo), with FAD (NQO1holo) and with FAD and the inhibitor dicoumarol 
(NQO1dic). We show that NQO1apo has a minimally stable folded core holding the protein dimer, 
with FAD and dicoumarol binding sites populating binding non-competent conformations. Binding 
of FAD significantly decreases protein dynamics and stabilizes the FAD and dicoumarol binding 
sites as well as the monomer:monomer interface. Dicoumarol binding further stabilizes all three 
functional sites, a result not previously anticipated by available crystallographic models. Our work 
provides an experimental perspective into the communication of stability effects through the NQO1 
dimer, which is valuable for understanding at the molecular level the effects of disease-associated 
variants, post-translational modifications and ligand binding cooperativity in NQO1. 
Keywords: protein structural dynamics; NQO1; ligand binding; protein stability; allostery; protein 
degradation 
 
1. Introduction 
Human NAD(P)H:quinone oxidoreductase 1 (NQO1; EC 1.6.5.2) is a multifunctional stress 
protein mostly localized in the cellular cytosol [1]. NQO1 expression is upregulated as a response to 
different types of cellular stress and through several mechanisms, including the antioxidant response 
through Nrf2-mediated and Ah2 signaling pathways [1–4]. 
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NQO1 displays multiple enzymatic and non-enzymatic functions [1–5]. NQO1 catalyzes 
different reactions with cytoprotective and metabolic roles, such as the two-electron reduction of 
quinones to form hydroquinones [2,6] (Figure 1), redox cycling of quinones [2], reduction of 
coenzyme Q10 and vitamin E to their antioxidant form [2], scavenging reactive oxygen species [1–3,7], 
reduction of catecholamines and vitamin K [1,2] and maintenance of the NADH/NAD+ redox balance 
[3,8]. The main features of these biochemical reactions involving NQO1 have been investigated in 
detail mainly through enzymological and structural analyses. Structurally, the enzyme forms obligate 
functional homodimers, with two active sites located in the monomer:monomer interface (MMI), and 
each monomer consists of two different domains: i) an N-terminal domain spanning residues 1–224 
that contains part of the active site and is involved in the tight binding of one FAD molecule per 
monomer and protein dimerization; ii) a C-terminal domain (residues 225–274) that contributes to 
stabilizing the protein dimer and to the binding of the NAD(P)H coenzyme and the substrates [1,4,9–
14]. The functional cycle of NQO1 generally involves two steps according to a ping-pong mechanism: 
first, in the reductive half-reaction, an NAD(P)H molecule binds to the enzyme and rapidly reduces 
the FAD to FADH2 (with a second-order rate constant of ~106 M−1·s−1) with the subsequent release of 
the oxidized nicotinamide dinucleotide; and second, in a very fast oxidative half-reaction (with a 
second-order rate constant >109 M−1·s−1), the substrate binds and is reduced by the FADH2, thus 
regenerating the flavin in oxidized form and releasing the reduced product [1,10]. This catalytic cycle 
is known to be inhibited by different coumarin-based molecules (the best characterized is the 
biscoumarin, dicoumarol) that act as competitive inhibitors by blocking the NAD(P)H access to the 
active site and partially occupying the NAD(P)H binding site [1,15]. Importantly, comparison of the 
crystal structures of NQO1 with FAD bound (NQO1holo) with that containing also dicoumarol bound 
(NQO1dic) have revealed that inhibitor binding causes only minor structural rearrangements in the 
conformation, which localize at the surface of the catalytic site [15]. Among non-enzymatic functions, 
we must highlight the ability of NQO1 to develop protein: protein and protein: RNA interactions 
[1,2,16–20]. In particular, protein:protein interactions involving NQO1 are relevant to understand its 
multiple roles in physiological and pathological processes. NQO1 interacts with key transcription 
factors associated with cancer (e.g., p53, p73α and HIF-1α) [17,18] and proteins involved in HIV 
infection (e.g., Tat protein) [19], and these interactions increase the intracellular stability of these 
protein partners by preventing their degradation by the proteasome. These protein:protein 
interactions presumably depend on the functional state of NQO1: binding of NADH may increase 
the strength of these interactions, while dicoumarol binding has the opposite effect [9,17,19]. In 
addition, NQO1holo binds to the 20S particle of the proteasome and inhibits its proteolytic activity, 
while FAD withdrawal (i.e., NQO1apo) renders NQO1 susceptible to degradation by this mechanism 
[16]. 
 
Figure 1. NQO1 catalyzes the two-electron reduction of a wide range of quinones. This enzyme also reduces 
other organic and inorganic species, such as superoxide radicals and iron(III) ions. 
Alterations in NQO1 stability and function are associated to different extents with a variety of 
human diseases, including cancer, neurological disorders (such as Parkinson´s and Alzheimer´s 
diseases, multiple sclerosis and schizophrenia) and cardiovascular diseases [1,21]. In these cases, 
either the wild-type (WT) NQO1 protein and/or a common polymorphic variant (rs1800566, causing 
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a Pro187Ser amino acid exchange) have been found to be associated with increased disease 
predisposition. The Pro187Ser variant decreases NQO1 activity due to a large defect in FAD binding 
(10- to 40-fold lower affinity than that of WT) and in conformational stability, leading to its rapid 
intracellular degradation by the proteasome [1,10,14,16,22–25]. In general, reduced NQO1 activity or 
protein levels are commonly observed under these pathological conditions [1,26], although for the 
particular case of cancer, overexpression of NQO1 is also associated with cancer progression, which 
makes pharmacological inhibition of NQO1 (e.g., by dicoumarol or related compounds) a potential 
therapeutic strategy to treat this disease if it selectively targets cancer cells [27–29]. Linked to some of 
these pathological conditions, the intracellular stability of NQO1 WT is controlled by the population 
of the NQO1apo state, which is efficiently targeted to the ubiquitin-dependent proteasomal 
degradation pathway [14,25,30]. Recent works also demonstrated that alterations in the 
phosphorylation pattern of NQO1 WT at different sites might be associated with these pathological 
states, likely through effects on the FAD binding affinity and consequently on the intracellular 
stability of NQO1 WT [26,30,31]. 
NQO1 is an excellent model to decipher the role of protein dynamics in the function and stability 
of flavin-dependent enzymes, the role of ligand binding in disease-associated protein stability, and 
the molecular mechanisms by which mutations cause loss-of-function genetic diseases 
[1,5,9,10,14,25,30–34]. FAD binding to NQO1 WT triggers a large conformational change, which can 
be observed by some biophysical techniques (circular dichroism, infrared and NMR spectroscopies 
or small-angle X-ray scattering), and increases the kinetic stability of the protein dimer, although 
high-resolution structural information is only available for the NQO1holo state [9–11,14,22,34,35]. This 
structural change is accompanied by significant changes in overall protein flexibility (evidence 
provided by proteolysis experiments and structure-based analyses of FAD binding energetics) 
[10,14,34], presumably linked to the fast degradation of NQO1apo vs. NQO1holo in the cell [14,25], 
although no high-resolution experimental information on these dynamic changes is available [14]. 
Regarding dicoumarol binding, the comparison of the X-ray crystallographic structures of NQO1holo 
and NQO1dic has revealed only local changes in protein structure at the active site [15], and thus, this 
did not provide details on the remarkable stabilizing effect of dicoumarol binding on the overall 
conformational stability and the dynamics of the C-terminal domain [14]. A critical role of protein 
dynamics in the mechanisms causing alterations in NQO1 function due to the Pro187Ser 
polymorphism and other rare cancer-associated mutations, phosphorylation at specific sites as well 
as the effect of suppressor mutations of the Pro187Ser phenotype have been put forward from 
experimental and computational studies [5,9,10,14,30–34,36]. Thus, they also await high-resolution 
information on the changes in protein dynamics due to these site-specific changes in different ligation 
states (NQO1apo, NQO1holo and NQO1dic). 
We report herein a detailed experimental analysis on the structural dynamics of human NQO1 
in three functionally relevant ligation states (NQO1apo, NQO1holo and NQO1dic). Our results uncover 
the existence of a dynamic network within the NQO1 dimer that readily responds to the binding of 
functional ligands and help to explain their effects on NQO1 function and stability in vitro and in vivo. 
Our work also provides an experimental benchmark to understand the allosteric effects of disease-
associated variants, post-translational modifications and ligand binding in NQO1. 
2. Materials and Methods 
2.1. Protein Expression and Purification 
Protein expression and purification was carried out as described [30]. E. coli BL21(DE3) cells 
were transformed with pET46 Ek/LIC vector containing the cDNA of human WT NQO1 [22] and 
grown for 16 h in LBA medium (LB containing 0.1 mg·ml−1 ampicillin at 37 °C). This culture was 
diluted 40-fold in fresh LBA and grown at 37 °C for 3 h. Expression was then triggered by the addition 
of IPTG (isopropyl β-D-1-thiogalactopyranoside) at a final concentration of 0.5 mM. Induced cells 
were incubated for 6 h at 25 °C, harvested by centrifugation, washed with binding buffer (BB, 20 mM 
sodium phosphate, 300 mM NaCl and 50 mM imidazole at pH 7.4) and frozen overnight at −80 °C. 
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Then, cells were thawed and resuspended in BB containing 1 mM PMSF (phenylmethylsulfonyl 
fluoride) and lysed by sonication. Crude extracts were clarified by centrifugation (20 min at 20,000× 
g and 4 °C), and supernatants were loaded into immobilized metal affinity chromatography (IMAC) 
columns (GE Healthcare) equilibrated in BB. Columns were washed with BB, and the protein was 
eluted with elution buffer (BB containing 500 mM imidazole). The eluate was exchanged to 50 mM 
K-HEPES (2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid, potassium salt) pH 7.4 using PD-
10 columns (GE Healthcare), centrifuged for 30 min at 20,000× g and 4 °C, and the UV–visible spectra 
of the supernatants were registered in a HP8453 UV–Visible spectrophotomer (Agilent). This purified 
holo-protein containing high levels of FAD bound (70%–80% based on the absorbance ratio at 450 nm 
and 280 nm; see also [30,33,36]) was stored at −80 °C upon flash freezing in liquid N2. Further 
purification of the NQO1 dimer was carried out by size-exclusion chromatography using a HiLoad® 
16/600 Superdex® 200 prep grade (GE Healthcare) and using 20 mM K-HEPES 200 mM NaCl at pH 
7.4 as the mobile phase. This purified protein was subsequently used to obtain apo-protein upon 
treatment with BB containing 2 M urea and 2 M KBr, 1 mM DTT (1,4-dithiothreitol) and 1 mM PMSF 
at 4 °C, and separation of the apo-protein and the FAD released was carried out by IMAC at 4 °C. 
Apo-proteins were finally exchanged to 50 mM K-HEPES at pH 7.4 using PD-10 columns at 4 °C, 
concentrated using VIVASPIN 6 30,000 MWCO PES devices (Sartorius) and stored at −80 °C after 
flash freezing in liquid N2. The purity and integrity of the holo- and apo-protein was checked by 
polyacrylamide gel electrophoresis in the presence of sodium dodecylsulphate (SDS-PAGE; Figure 
S1). The holo-protein was also found to display enzyme kinetic parameters (Figure S1) consistent 
with those previously reported using the same protein construct and purification procedure [9,22]. 
Purified proteins were also verified by mass spectrometry. The intact mass was analyzed 
through direct infusion on ESI-FT-ICR MS (Figure S2), showing that the protein was expressed intact 
and lacking the N-terminal Met. The dimeric state of NQO1apo and NQO1holo was verified by native 
ESI-MS (Figure S3). 
2.2. Hydrogen/Deuterium Exchange Mass Spectrometry (HDXMS 
Amide hydrogen/deuterium exchange (HDX) of NQO1 was followed for its apo (NQO1apo) and 
holo (NQO1holo) forms, and the holo form was also analyzed in the presence of dicoumarol (NQO1dic). 
Prior to the exchange, the NQO1holo and NQO1dic at 20 μM concentration were pre-incubated with 10 
molar excess of FAD for 5 min. NQO1dic was then further mixed with 10 molar excess of dicoumarol 
and incubated for another 5 min. The exchange reaction was initiated by a 10-fold dilution into a D2O-
based 50 mM K-HEPES, pD 7.4, 1 mM TCEP (tris(2-carboxyethyl)phosphine). The exchange was thus 
followed at 2 μM protein concentration. Deuterium labelling was quenched by 0.5 M Glycine-HCl, 
pH 2.3, which was added at 1:1 ratio. The samples were then frozen in liquid N2. Exchange was 
followed for 10 s, 30 s, 2 min, 5 min, 20 min, 1 h and 3 h, where 10 s, 5 min and 3 h samples were done 
in replicate. Each sample was quickly thawed and injected into a cooled LC system. Here, the protein 
was digested on custom-made nepenthesin-2 (Nep-2) and pepsin columns coupled in tandem (each 
having a bed volume of 66 μL), and the resulting peptides were trapped on a VanGuard Pre-column 
(ACQUITY UPLC BEH C18, 130Å, 1.7 μm, 2.1 mm × 5 mm, Waters, Milford, MA,USA), where they 
were desalted. The solvent used for digestion and desalting (0.4% formic acid (FA) in water) was 
pumped by a 1260 Infinity II Quaternary pump (Agilent Technologies, Waldbronn, Germany) at a 
flow rate of 200 μL·min−1. After three minutes of digestion and desalting, the peptides were separated 
on an analytical column (ACQUITY UPLC BEH C18, 130 Å, 1.7 μm, 1 mm × 100 mm, Waters, Milford, 
MA, USA) using linear gradient (5%–45% B in 7 min) followed by a quick step to 99% B lasting 5 min. 
Solvent A was 0.1% FA/2% acetonitrile (ACN) in water, B was 0.1% FA/98% ACN in water. The 
gradient was delivered by the 1290 Infinity II LC System (Agilent Technologies, Waldbronn, 
Germany) at a flow of 40 μL·min−1. Digestion, desalting and separation were done at 0 °C and pH 2.3 
to minimize deuterium loss. The LC system was connected directly to an electrospray ionization 
source of a 15T FT-ICR mass spectrometer (solarix XR, Bruker Daltonics, Bremen, Germany) 
operating in broad-band MS mode. Data were peak-picked and exported using DataAnalysis v. 5.0 
(Bruker Daltonics, Bremen, Germany) and then processed by the in-house developed program 
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Deutex (unpublished). Peptides arising from the digestion were identified through separate data-
dependent LC-MS/MS analyses (using the same setup as described above) and database searching 
by the MASCOT algorithm v. 2.4 (Matrix Science, London, United Kingdom) against a custom-build 
database containing sequences of pepsin, nepenthesin-2 and NQO1. Fully deuterated samples were 
prepared and used for back-exchange correction as described previously [37,38]. Differences in 
deuteration can be considered as significant if they exceed 0.25 Da (calculated as 3× the average 
standard deviation). 
The optimization of digestion conditions, including numerous proteolytical setups, showed that 
the serial combination of nepenthesin-2 with pepsin, operated at 200 μL·min−1, provided the best 
results in terms of sequence coverage (98.9%, missing the last three amino acids), number of peptides 
(140), average peptide length (8.3) and redundancy (4.1) (Figure S4). At this point, it should be also 
noted that the region between 100 and 110 yielded peptides of considerable hydrophobicity for which 
the signal intensity/quality was just at the threshold level, and thus conclusions derived from their 
analyses must be made with caution. The redundant peptide set was used to calculate deuteration in 
the shortest possible segments using the overlapping peptides. This analysis provided more detailed 
non-redundant information (high-resolution set). Data in this high-resolution set are mainly 
described in the manuscript (Figures 2–7, Figure S6 and Table S1), while those using experimental 
peptides (low resolution set) are found in Figures S7–S11 and Table S2. Note that the high-resolution 
set essentially leads to the same key conclusions as the low resolution one but, in principle, the former 
narrows the region for which HDX kinetics is assessed. 
To report data on NQO1 segments from HDXMS, we did not consider the His-tag and used the 
native sequence from Met1 to Lys274. Therefore, the numbering used throughout the manuscript 
differs from that reported in some crystal structures of NQO1, which did not include Met1 and thus 
numbered the residues from Val1 to Lys273 (Val2 to Lys274 in the native sequence). 
3. Results and Discussion  
3.1.A Stable Folded Core in NQO1apo with Highly Dynamic Functional Sites 
The results of HDX kinetics for NQO1apo are shown in Figure 2A. Results are presented as the % 
of the maximal (theoretical) deuterium incorporation for each segment (%D). Virtually all peptides 
characterized in this work for NQO1 complied with EX2 behavior (the presence of a tiny contribution 
from the EX1 regime can be detected in a few NQO1 peptides; see Figure S5). In the EX2 mechanism, 
the intrinsic exchange rate constant (kint) is much lower than the rate constant (kcl) for the conversion 
between non-exchanging (NE-NH) and exchanging (E-NH) states, according to the Linderstrøm-
Lang model (Scheme: 1): 
kop kint  
𝑁𝐸−𝑁𝐻 ↔ 𝐸−𝑁𝐻 → 𝑒𝑥𝑐ℎ𝑎𝑛𝑔𝑒𝑑 𝑁𝐻  
kcl  
Scheme 1. Linderstrøm-Lang model for HDX kinetics. 
Assuming a pure EX2 behavior, the rate constant for exchange of individual backbone amides 
would be equal to the product of the equilibrium constant between NE-NH and E-NH (Kop = kop/kcl) 
and kint [39]. Therefore, for this very simple mechanism (note that the conformational equilibrium is 
simply two-state and experimental HDX is rarely pure EX2), the experimental rate constant for 
exchange reflects to some extent the local stability (e.g., due to hydrogen bonding and burial in the 
structure) of the secondary structure. 
Overall, the HDX kinetics was very heterogeneous among different protein segments of 
NQO1apo (Figure 2A). Most of the segments showed fast HDX kinetics (typically exchanging more 
than 20%D in the seconds-minutes time scales) while only a few peptides showed essentially no 
exchange after 3 h (%D < 20). Thus, in a first approach, we simply discerned between exchanging and 
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non-exchanging segments considering the %D after 3 h (%D < 20 vs. %D ≥ 20, respectively). The 
functional implications of this simple analysis were considered regarding those residues in different 
segments belonging to three functional sites: the FAD binding site (FBS), the dicoumarol binding site 
(DBS) and the monomer: monomer interface (MMI)(see Figure 2A), as provided by analysis of an X-
ray crystallographic structure (PDB 2F1O [15]). It is worth noting that in this structure, the FBS and 
DBS are located adjacent to each other in the NQO1 monomer (actually, FAD is structurally part of 
the DBS), and both sites are close to the MMI (Figure 2B). Importantly, most of the residues that 
belong to the FBS, DBS and MMI are classified as exchanging in NQO1apo (%D ≥ 20; Figure 2A,B). 
Figure 2. Overall HDX kinetics of NQO1apo. (A) HDX kinetics for segments of NQO1apo. Residues belonging to 
the monomer: monomer interface (MMI), FAD binding site (FBS) and dicoumarol binding site (DBS) are 
indicated as colored circles. These sites were retrieved from the analysis of the NQO1 structure (PDB 2F1O; [15]) 
using the PISA server (https://www.ebi.ac.uk/pdbe/pisa/); (B) Structural representation of HDX after 3 h [%D (3 
h)] in NQO1apo. For visual aid, the left panel shows the location of bound FAD and dicoumarol, the middle panel 
shows those residues belonging to the MMI, FBS and DBS, and the right panel displays the %D after 3 h for 
residues belonging to these functional sites. 
Within non-exchanging segments, we found that these contained mostly residues buried in the 
crystallographic structure of NQO1 (in a ternary complex with FAD and dicoumarol bound, PDB 
2F1O; NQO1dic) (Figure 3A). Thus, these sequences likely represent regions that are critical for the 
acquisition and maintenance of a minimally stable dimeric fold in NQO1apo (note that NQO1apo is 
dimeric in solution but more expanded and flexible, and with lower conformational stability, than 
NQO1holo [9,14]). This minimal core involves helices α1, α3 and α4 and sheets β1 and β3–β5 (Figures 
3A and S8). This core may also contribute to the acquisition of a minimally folded monomeric state 
that becomes stabilized in the dimeric state by the interactions between helices α3 and α4 across the 
monomers (i.e. the MMI) (Figures 3B and S8). 
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Figure 3. Non-exchanging segments define a minimally stable core in NQO1apo. (A) Plot of the % 
SASA (solvent accessible surface area) for individual residues (considering backbone and side-chain) 
calculated from the structure of NQO1dic (PDB 2F1O [15]) using GETAREA 
(http://curie.utmb.edu/getarea.html; this algorithm does not consider the ligands in the calculation). 
Secondary structure elements are depicted according to [11]; residues belonging to non-exchanging 
segments are displayed as green circles; (B) Structural representation of non-exchanging segments 
(using PDB 2F1O [15]). The left panel shows a surface representation highlighting the burial of the 
minimally stable core. The middle panel shows segments belonging to this core plotted onto 
secondary structure elements. The right panel shows that this core may contribute to the stable folding 
of the individual monomers as well as their assembly into the dimer, with only a few stable contacts 
with the FAD (in orange ball representation) and the dicoumarol (in yellow ball representation). 
Importantly, the FBS and DBS in NQO1apo are overall exchanging (Figures 2B, 3B and S8B), with 
the main exceptions being some marginal contacts in helices α1 and α3 (FBS) and α4 (DBS) (Figures 
3B and S8B). Thus, our HDX analyses support that the conformational ensemble of NQO1apo is 
essentially populated by states non-competent for FAD or dicoumarol binding due to the high 
structural dynamics of their binding sites [9,14,34]. 
3.2. Complex HDX Kinetics 
To provide deeper insight into the structural dynamics of NQO1apo, we carefully analyzed the 
HDX kinetics for all protein segments (Figure S6). It should be noted that these HDX kinetics were 
very consistent with those obtained directly from peptides experimentally characterized (Figure S7 
and S11). For the majority of the cases, HDX kinetics was described very well by a simple function 
with two kinetic phases (see Figures S6 and S7 for fittings, and Tables S1 and S2 for the best-fit values): 
a burst-phase corresponding to HDX mostly occurring within the experimental dead time (i.e., very 
few seconds), and thus characterized by a single parameter: its amplitude Aburst; and a slow phase 
that occurred typically in a scale of several seconds to minutes, characterized by two parameters: its 
amplitude Aslow and an apparent first-order rate constant (kslow), following this equation: % 𝐷ሺ𝑡ሻ =  𝐴௕௨௥௦௧ + 𝐴௦௟௢௪ · (1 − 𝑒𝑥𝑝ି௞ೞ೗೚ೢ·௧) 
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We chose to use this phenomenological description of HDX kinetics mainly for two reasons. 
First, it provided a simple scenario from which, using three characteristic parameters (Aburst, Aslow and 
kslow), we could compare the HDX kinetics of different segments of NQO1apo (see Figure 4; note that 
this approach also worked very well with the HDX kinetics of NQO1holo and NQO1dic; see Figures S6–
S7 and Tables S1–S2). Second, although HDX kinetics analyzed using more complex functions (e.g., 
the two kinetic phases each containing a characteristic rate constant) may provide in some cases better 
fits, this would put the analyses at two intertwined risks: increasing the fitting parameters would 
make comparisons between behaviors more difficult, and importantly, in many cases these fittings 
show evident signs of overparametrization. 
Kinetic analyses of HDX for protein segments considered as exchanging (>20%D after 3 h) 
revealed certain interesting behaviors. First, for many protein segments (of different lengths), we 
observed a significant contribution to the HDX kinetics from both the burst and slow phases (Figures 
4 and S9, and Tables S1–S2). As indicated above, the HDX kinetics of NQO1 in all three ligation states 
is vastly consistent with EX2 kinetics, and thus, the observed kinetics depends to some extent on the 
equilibrium constant between non-exchanging and exchanging states [40]. Therefore, the presence of 
two clearly differentiated kinetic phases suggests the existence of complexity (i.e., heterogeneity) in 
the conformational ensemble of NQO1apo, and plausibly, the significant population of at least two 
conformational substates with different HDX behavior, which may or may not significantly 
reequilibrate upon the intrinsic HDX step. Interestingly, although ligand binding affects these two 
kinetic phases (NQO1holo and NQO1dic, see Figures S6–S7 and Tables S1–S2), both these phases still 
contribute to the HDX kinetics in these ligation states, suggesting that a certain degree of 
conformational heterogeneity remains upon ligand binding. Second, although in the EX2 scenario the 
overall kinetics depends on the intrinsic HDX rate constant, and therefore, on the individual 
backbone amides and their vicinity [40], some sort of correlated behavior at larger scales than small 
protein segments (e.g., secondary structure elements) is observed (Figures 4B and S9). Consistent 
with the above-mentioned proposal of a stable core of NQO1apo with highly dynamic FBS and DBS 
(simply made by analysis of %D after 3 h, Figure 3), these kinetic analyses suggest that secondary 
structure elements outside the stable core typically exchanged quite fast (i.e., with large burst phases 
and with kslow often in the range of 10−1 to 10−2 s−1; Figures 4B and S9). 
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Figure 4. Segment-specific HDX kinetics of NQO1apo. (A) Fittings of HDX kinetics for selected 
segments typically showing at least 50%D incorporation after 3 h and considered part of the functional 
sites (MMI, FBS and DBS). (B) Plots of the amplitudes for the burst- and slow-phase in HDX for 
segments (upper panel) and rate constants for the slow phase (lower panel) for segments with at least 
20%D after 3 h. The elements of the secondary structure along the protein sequence are also indicated. 
3.3. FAD and Dicoumarol Binding Cause Large-Scale Changes in Protein Structural Dynamics  
FAD binding to NQO1apo is known to cause significant overall changes in protein structure and 
dynamics: it increases the content in the ordered secondary structure, reduces the protein 
hydrodynamic volume, and substantially enhances protein stability and resistance towards 
proteolytic attack [9,14,22,34,35]. In addition, structural and biophysical analyses have shown that 
NQO1 must contain bound FAD in order to bind dicoumarol with high affinity [9,14]. We first 
compared the %D incorporated to NQO1holo and NQO1apo after 3 h of reaction (Figure 5A–B), 
observing some interesting changes upon FAD binding. Particularly large differences were observed 
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in loop L1 (involved in the MMI and the FBS), loop L4 (involved in the MMI, the FBS and the DBS) 
and helix α5 (involved in the FBS). The stabilization observed for the MMI thus explains the increased 
thermostability of the NQO1 dimer upon FAD binding. The much lower structural dynamics of the 
FBS upon FAD binding is also consistent with an induced-fit mechanism, in which binding competent 
states (with high structural stability) are marginally populated in the absence of FAD, according to a 
recent proposal based on binding structure-thermodynamic relationships [34]. Interestingly, these 
results also imply that FAD is not only required for dicoumarol binding as a part of the DBS, but also 
that FAD binding modifies the dynamics of protein structural elements involved in the binding of 
the inhibitor (Figure 5C). It is worth noting that FAD binding also significantly slows down (3- to 5-
fold) HDX of other regions such as sheet β6, helix α7 and loop L3 (Figures 6 and S6, and Table S1), 
some of them not directly involved in the MMI, FBS or DBS. 
 
 
Figure 5. Overall HDX kinetics for segments of NQO1 upon binding FAD and dicoumarol. (A and B) HDX for 
segments of NQO1apo, NQO1holo and NQO1dic. Panel A shows %D after 3 h, and Panel B the difference in this 
parameter (Δ%D) between NQO1holo or NQO1dic and NQO1apo. Residues belonging to the MMI, FBS and DBS are 
indicated (retrieved as described in Figure 2). (C) Δ%D after 3 h in NQO1 upon FAD and dicoumarol binding 
plotted onto the NQO1 structure (PDB 2F1O). For comparison, the left panel shows the location of MMI, FBS 
and DBS, the middle and right panels show those residues belonging to the sites that displayed at least a decrease 
of 10%D after 3 h in NQO1holo (middle panel) or NQO1dic (right panel) vs. NQO1apo. 
Dicoumarol binding to NQO1holo is also known to increase the protein ordered secondary 
structure, thermal stability and resistance of the N-terminal domain towards proteolysis [9,14]. 
According to this evidence, we observed that dicoumarol binding to NQO1holo decreased the %D after 
3 h to an even larger extent than FAD binding, and these effects seemed to propagate to more distant 
regions in the protein structure, extensively affecting regions involved in the MMI, the FBS and DBS 
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(Figure 5). The regions affected by dicoumarol binding were actually the very same set of structural 
regions affected by FAD binding with the exception of helix α5 (Figure 5). In contrast to FAD, 
dicoumarol binding also caused a dramatic reduction in %D in sheet β4 and loop L5, which contain 
residues belonging to the MMI and the DBS (Figure 5). In addition, dicoumarol binding slowed down 
the HDX kinetics of helix α7 and loops L4 and L5 (Figures 6 and S6–S7, and Tables S1–S2) by several 
orders of magnitude. 
Figure 6. Changes in segment-specific HDX kinetics of NQO1 upon FAD and dicoumarol binding. 
Right panels show fittings of HDX kinetics for selected individual segments using a single exponential 
function with a burst-phase for NQO1apo (grey), NQO1holo (black) and NQO1dic (red). These data were 
used to calculate Δ%Dav, as an average of the time points with maximal differences between a given 
NQO1 form (NQO1holo, black; NQO1dic, red) and NQO1apo, as a single metric to quantify changes in 
HDX kinetics (left panels). 
Clearly, the HDX kinetics of NQO1 in all three ligation states (NQO1apo, NQO1holo and NQO1dic) 
were complex overall (Figures 6 and S6–S7). Therefore, it was not straightforward to provide a single 
metric from the global kinetic analysis reported so far in this work, even when a simple kinetic model 
was used. To quantify the effects of ligand binding (and potentially of mutations) on the structural 
dynamics of NQO1, we sought a single metric that would respond, at least semi-quantitatively, to 
the different types of change observed upon ligand binding (Figure 5 and 6). We must note that these 
changes include a variety of effects on the amplitudes of the two kinetic phases (sometimes 
increasing, decreasing, not changing or even shifting between the amplitudes of the burst and the 
slow phases upon ligand binding) and also on the rate constant of the slow phase (in some cases, this 
phase was too fast or slow to be measured adequately) (see Tables S1 and S2). Notably, all these 
effects on the HDX kinetics can be simplified to a common effect: at least a few of the data in the time-
dependent measurements differ from two samples when these samples are paired for a given time 
point (see Figure 6 for representative examples). Thus, we decided to simply calculate the difference 
between the two paired proteins species for a given time and protein segment, and for each segment, 
to average the three time points with a maximal difference in these time series. Indeed, this simple 
metric (called  Δ%Dav) was able to detect and rank the effects of ligand binding on NQO1 HDX due 
to changes in amplitudes and kinetic rate constants (Figure 6). 
We compared again the behavior of NQO1holo vs. NQO1apo using Δ%Dav (Figures 7A and S10A). 
The results showed that FAD binding substantially reduced the backbone dynamics of residues 11–
20 (loop L1 and helix α1), 46–76 (loops L2 and L3, helix α7 and sheet β6), 103–113 (sheet β6 and loop 
L4), 149–165 (loop L6) and 191–211 (loop L7 and helix α5) (Figure 7A). These regions include most of 
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the residues involved in the MMI and FBS, and also some belonging to the DBS (Figure 7A–B). When 
we evaluated the effect of dicoumarol binding, we observed further structural stabilization of all 
these regions (with the exception of residues 191–211) and a specific stabilization of two additional 
regions mostly involved in the MMI and DBS: a dramatic stabilization of the segment 120–141 (loop 
5) and a moderate effect in the segment 223–240 (loops L8 and L9 and sheets β8 and β9). 
 
Figure 7. Changes in HDX kinetics of NQO1 upon binding FAD and dicoumarol as changes in %Dav (Δ%Dav). 
(A) Δ%Dav for NQO1 segments upon binding FAD (NQO1holo) and dicoumarol (NQO1dic), using NQO1apo as a 
reference. Residues belonging to the MMI, FBS and DBS are indicated (retrieved as in Figure 2). (B) 
Representation of Δ%Dav onto the structure of NQO1 (using PDB 2F1O). The upper row shows results for the 
Δ%Dav of NQO1holo and the lower row represents NQO1dic. Different panels in each row show results for residues 
involved in the FBS, DBS or MMI. 
3.4. Insights into Cooperative Effects upon FAD and Dicoumarol Binding from Analysis of Structural 
Dynamics 
In addition to the overall conformational and functional consequences of FAD and dicoumarol 
binding to NQO1, some experimental techniques have revealed complexity in the functional 
chemistry of this enzyme [22,23,41]. This behavior is not unexpected since binding of FAD to NQO1apo 
and dicoumarol to NQO1holo is described by a general formalism for binding of a ligand (L) to a 
macromolecule (P, NQO1 dimer) with two binding sites (Scheme 2) [42]: 
 
Scheme 2. General formalism for a macromolecule P (NQO1 dimer) with two ligand (L) binding 
sites. 
in which K1 and K2 describe the step-wise equilibrium constants as follows: 
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𝐾ଵ = [𝑃𝐿][𝑃] · [𝐿] 
𝐾ଶ = [𝑃𝐿ଶ][𝑃𝐿] · [𝐿] 
For a P with two equivalent and non-interacting binding sites, these two step-wise equilibrium 
binding constants are related through a simple relationship: K1 = 4·K2. Significant deviations from this 
relationship imply the existence of non-equivalent or interacting sites: K1 > 4·K2 implies either 
negative cooperativity or non-equivalent binding sites, while K1 < 4·K2 unequivocally identifies 
positive cooperativity. It must be noted that, in this scenario, the largest differences between 
cooperative and non-cooperative binding are found for the dependence of the population of the half-
ligated species [PL] (e.g., NQO1 dimer with one FAD bound) on [L] [22,23,42]. 
The NQO1 dimer contains two binding sites for either FAD or dicoumarol. Interestingly, 
calorimetric titrations of NQO1apo with FAD and NQO1holo with dicoumarol, as well as inhibition 
studies in the case of dicoumarol, have identified the existence of negative cooperativity in the 
binding of both ligands [22,23,41]. A detailed structural characterization of the communication 
between ligand binding sites underlying these cooperative effects is challenging for several reasons. 
First, in the ligand binding equilibrium, the unligated (P), half-ligated (PL) and fully-ligated (PL2) 
species contribute structurally and energetically to the observed cooperative binding. However, to 
date, no structural information on the P or PL states for FAD binding is available (i.e., no high-
resolution structure of NQO1apo or the intermediate species with a single FAD molecule bound per 
dimer), while for dicoumarol binding, no structural information for PL (NQO1holo with a single 
dicoumarol molecule bound per dimer) is available. Although our current HDXMS study does not 
report on half-ligated species, we were able to identify a network of interacting residues in NQO1apo 
that connect structurally and energetically the FBS and the DBS between monomers through the MMI 
interface. Therefore, our results suggest the existence of a highly dynamic structural network 
connecting these binding sites between the monomers in NQO1, and these results may also provide 
a blueprint for future experimental and computational mutagenesis studies aimed at perturbing and 
analyzing the role of this network in ligand binding energetics and cooperativity. In support of this 
hypothesis, recent work has shown that the mutation Gly151Ser (Gly150 according to the crystal 
structure) essentially prevents the communication of ligand binding effects between the two DBS 
across the NQO1 dimer [41]. Gly151 is located in the beginning of loop L6, and it undergoes a 
noticeable decrease in structural dynamics upon dicoumarol binding (Figure 7), which might 
constitute part of the allosteric signal generated by dicoumarol binding to one site (to form the half-
ligated state PL), which communicates to the other subunit contributing to the negative cooperativity 
for dicoumarol binding. More globally, our analyses from HDXMS support the idea that dicoumarol 
binding triggers changes in NQO1 dynamics for certain (but not all) regions predicted by studies 
using a Gaussian network approach on structural models for the P and PL states [41]. In agreement 
with this recent study, we observed that dicoumarol binding affected the dynamics of loops L3 and 
L5, sheets  β6 and β7, and helices α2, α5 and α7, which showed the largest changes in dynamics when 
the slowest frequency modes were analyzed upon formation of the PL state by a Gaussian network 
model (Figure 7 vs. [41]). 
4. Conclusions 
The multifunctional nature of NQO1 is likely controlled, to a large extent, by changes in protein 
structural dynamics triggered by the binding of small molecules (FAD, NAD(P)H, substrates, 
inhibitors) as well as by interaction with other biomacromolecules (proteins and nucleic acids). These 
structural and energetic aspects are critical to improve our understanding of these interactions under 
physiological and pathological conditions. In this work, we showed that the use of HDXMS can be 
instrumental to provide unprecedented detail of the effects of ligand binding on the functional 
chemistry of NQO1 linked to changes in protein structural dynamics. This approach may provide 
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novel insights into the regulation of NQO1 activity and stability in vivo, as well as the mechanisms 
by which these properties are regulated and/or dysregulated by disease-associated single amino acid 
exchanges and post-translational modifications. 
NQO1 is one of the human flavoproteins for which intracellular protein levels are more strongly 
coupled to the intracellular availability of the flavin cofactor [25]. Our current understanding of this 
phenomenon proposes that this sensitivity of protein stability is due to efficient recognition and 
degradation of human apo-flavoproteins by the ubiquitin-dependent proteasomal pathway 
[14,25,30]. The lack of high-resolution information on the structure and dynamics of human apo-
flavoproteins, due to the instability of these apo-proteins, has prevented us from a deep 
understanding of these recognition mechanisms. The detailed analysis reported herein for NQO1apo 
supports that HDXMS can also be used to improve our understanding of this phenomenon as well 
as the mechanisms by which disease-associated mutations and post-translational modifications may 
alter protein structural dynamics, leading to alternative recognition mechanisms by the proteasomal 
degradation pathway [14,30,34,36]. 
In this work, we identified a minimally stable core that allows NQO1apo to exist as a dimer, 
although this dimer constitutes a highly dynamic conformational ensemble and with marginal 
conformational stability. This core may serve as a wiring network that allows the communication of 
ligand binding and mutational effects between domains and between subunits through this 
minimally stable MMI (see [9,22,23,32,33]), and cooperative effects upon FAD and dicoumarol 
binding [22,23,41]. 
Our study also allows us to discuss the deleterious effects of the common cancer-associated 
polymorphism Pro187Ser. Pro187 belongs to sheet  β5, as a part of the stable core of the monomer in 
NQO1apo state (Figure 3). Thus, the strong structural perturbation presumably caused by Pro187Ser 
substitution could readily cause long-range effects on the structural dynamics of NQO1apo by 
disrupting this stable core, and these effects could propagate within the monomer and between 
subunits in the dimer. This interpretation agrees with previous experimental, computational and 
structural perturbation analyses carried out on the Pro187Ser variant [5,14,22,30–34,36]. 
Consequently, even in NQO1apo, the cancer-associated polymorphism Pro187Ser would destabilize 
the NQO1 monomer, and this effect could easily propagate to the MMI, the FBS and the DBS, thus 
contributing to explain the low conformational stability of P187S in vitro, its low affinity for FAD and 
dicoumarol, and its accelerated degradation by the proteasome [9,10,14,22–25,34]. 
Our analyses also support that HDXMS can provide unprecedented structural insight into the 
catalytic cycle of NQO1. First, our results indicate that FAD binding shifts the conformational 
ensemble of NQO1 towards more stable and competent states for either NAD(P)H or dicoumarol 
binding (i.e., at the DBS). This effect is further strengthened upon the binding of the inhibitor, 
suggesting that the structural dynamics of the DBS (and plausibly of the NAD(P)H binding site; [15]) 
acts by limiting the available ligand binding poses of NAD(P)H. This would optimize hydride 
transfer from the adenine dinucleotide coenzyme to the FAD, thus contributing to high rate constants 
experimentally measured for the reductive half-reaction catalyzed by NQO1 [10]. 
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